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Abstract
Purpose: The beneﬁ  t of neoadjuvant therapy for tumours above the peritoneal reﬂ  ection is not clear. The purpose of this 
study is to demonstrate the feasibility and downstaging of treating locally advanced tumours from high rectum to distal 
sigmoid with preoperative chemoradiotherapy (CRT).
Methods and Materials: Seventeen patients with high rectal, recto-sigmoid or distal sigmoid tumours above the peritoneal 
reﬂ  ection received neo-adjuvant CRT, selected on MRI ﬁ  ndings indicating T4 disease or threatened circumferential resec-
tion margin. All patients were administered neoadjuvant chemotherapy, with Oxaliplatin or Mitomycin C and a Fluoropy-
rimidine. The pelvis received long-course CT-planned conformal RT, 45 Gy in 25 fractions, with a boost of 5.4–9 Gy in 3–5 
fractions. Thirteen patients were treated with concomitant oral or intravenous Fluoropyrimidine chemotherapy.
Results: Median follow-up was 37 months. Overall survival was 82.35% (95% Conﬁ  dence Interval (CI) 54.7–93.9) and 
disease free survival 81.25% (95% CI 52.5–93.5). Only 1 patient suffered loco-regional relapse. Chemotherapy regimens 
were well tolerated, though some patients required dose reductions. Nine patients (52.9%) lowered pathologic disease AJCC 
stage, i.e. ‘downstaged’. Six patients (35.3%) achieved complete pathological response. Clear margins were attained in all 
but 1 patient. Three patients were converted from cT4 to ypT3. No patient required a gap during CRT. One patient suffered 
a grade III acute toxicity, but no grade IV (RTOG). There were 3 grade III and 3 grade IV late toxicities (LENT-SOMA).
Conclusions: Locally advanced high rectal and recto-sigmoid tumours may be treated with pre-operative CRT with accept-
able toxicity, impressive down-staging, and clear surgical margins.
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Introduction
The position of tumours within the rectum, in terms of their height above the anal verge, inﬂ  uences the 
likelihood of local control and also the impact that radiotherapy has on achieving local control. Low 
tumours requiring abdomino-perineal resection (APR) carry a much higher local recurrence rate com-
pared with those tumours that are treated by anterior resection (Marr et al. 2005). This at any rate applies 
when a conventional APR technique is employed which, by following normal anatomy contours, means 
that the resection margin is very close to tumour in the region of the origin of the levators. As a result, 
there is a far higher rate of histopathological margin positivity in the resected specimen following APR. 
For these low tumours, neoadjuvant radiotherapy reduces local failures in operable tumours and provides 
useful down-staging in locally advanced disease (Sauer et al. 2004).
For tumours higher in the rectum, and those at the recto-sigmoid junction, the beneﬁ  t of neoadjuvant 
therapy is not as clear. In the Dutch Colorectal Cancer Group Trial, randomising patients undergoing 
total mesorectal excision to neoadjuvant short course radiotherapy, there was no signiﬁ  cant beneﬁ  t in 
terms of local control in tumours situated 10.1–15 cms from the anal verge (Kapiteijn et al. 2001). This 
was in contrast to tumours located lower in the rectum with both tumours arising between 5 and 10 cms, 
and those below 5 cms from the anal verge, showing a signiﬁ  cantly reduced local recurrence rate. This 
is an intuitive result with radiotherapy being able to provide a beneﬁ  t in the location which is most 
likely to be associated with positive surgical resection margins. However, although it’s easy to deﬁ  ne 136
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the location of very low tumours, because of their 
accessibility to the examining ﬁ  nger and easier 
measurement of distance from the anal verge on 
imaging, it becomes increasingly difﬁ  cult to deter-
mine the position of tumours higher in the rectum 
and in establishing the position of the recto-
sigmoid junction. The variability of measurement 
on sigmoidoscopy is well recognised and the divi-
sion of the rectum by strict centimetre criteria is 
unrealistic on an individual basis. The lack of 
clarity in agreement in the available randomised 
data as to how tumours are designated as rectal, 
as opposed to sigmoid, means that high rectal, 
rectosigmoid and even distal sigmoid cancers are 
sometimes included in rectal cancers series. A 
useful anatomical marker is the peritoneal reﬂ  ec-
tion which prior to MRI could not be reliably 
located, except at surgery. The peritoneal reﬂ  ec-
tion is a critical marker as the tissues inferior to 
this structure form a discreet compartment which 
can be encompassed within a radiotherapy target 
volume, whereas tumour above this structure is 
considered likely to disseminate within the peri-
toneal cavity and be beyond the scope of a useful 
and tolerable radiotherapy volumes (Pilipshen 
et al. 1984). For this reason, there is a generally 
held perception that neoadjuvant radiotherapy is 
not appropriate for high rectal and rectosigmoid 
tumours, having a greater potential for acute and 
chronic side-effects, due to the proximity of small 
bowel, without the potential level of efﬁ  cacy 
achieved with tumours in the low to mid rectum. 
Consequently, radiation oncologists can be biased 
against the application of neoadjuvant or adjuvant 
radiotherapy for these tumours.
For rectal cancer, it is now appreciated that the 
margin of excision and the risk of a positive cir-
cumferential resection margin (CRM) can be 
accurately predicted by high spatial resolution 
pre-operative MRI (MERCURY, 2006). Recently, 
it has been shown that this ability to accurately 
identify and stage tumours pre-operatively by 
MRI can be extended to tumours in the upper 
rectum, rectosigmoid and distal sigmoid (Burton 
et al. 2006). A group of patients with MRI deﬁ  ned 
threatened CRM and T4 tumours situated either 
in the high rectum, recto-sigmoid or distal sig-
moid have been treated in our institution with a 
neoadjuvant CRT schedule with the aim of down-
staging prior to surgery. Such a group has not been 
previously identiﬁ  ed in any of the trials using 
CRT in locally advanced disease. In this article 
the feasibility of applying such a strategy to these 
high tumours is demonstrated and the subsequent 
down-staging, 3 year local failure rate and 
survival is presented.
Methods and Materials
Study population
Seventeen patients with high rectal, recto-sigmoid 
or distal sigmoid received neo-adjuvant CRT in 
an attempt to downstage their tumours pre-
operatively. They were selected on the basis of 
MRI ﬁ  ndings which indicated either a T4 tumour 
or T3 tumour with a ‘threatened’ CRM, and dis-
cussed at the centre Multi-Disciplinary meeting. 
A threatened CRM is deﬁ  ned as tumour or nodal 
disease on MRI at or within 1 mm of the meso-
rectal fascia, the boundary of dissection in total 
mesorectal excision (TME). All tumours were 
located above the peritoneal reﬂ  ection. Based on 
MRI assessment, the lower border for upper rectal 
tumours was deﬁ  ned as 10 cm above the anal 
verge, for recto-sigmoid tumours 12 cm, and for 
distal sigmoid tumours 15 cm.
Pre-operative MRI technical details
Pre-operative supine T2 MR scanning was 
performed on a 1.5T Siemens scanner with a 
4-element pelvic phased array wrap-around sur-
face coil. Intravenous contrast was not used. All 
scans were reviewed by a single radiologist 
(GB).
Radiotherapy technical details
All patients received megavoltage radiation (6 
or 10 MV) via 2-phase CT-planned conformal 
RT (see Fig. 1). A planning CT scan was per-
formed in the treatment position, with an anal 
marker. Patients were treated prone with a full 
bladder. A 3 or 4 ﬁ  eld technique was used for 
both phases, with segmented low-weighted ﬁ  elds 
to reduce ‘hot-spots’ where necessary. Conformal 
blocks or multi-leaf collimators (MLC) were 
used on all fields. Treatment planning was 
performed with computerized dosimetry and the 
prescribed dose speciﬁ  ed according to ICRU 50 
guidelines (1993). All ﬁ  elds were treated each 
day, 5 days a week. Electronic Portal Imaging of 
each field was performed daily for the first 137
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4 fractions. Further imaging was not routinely 
performed once images were within a 5 mm 
tolerance in all planes.
Departmental policy for pre-operative RT for 
rectal cancer is to treat the pelvis with long-course 
RT, 45 Gy in 25 fractions at 1.8 Gy per fraction, 
with concomitant chemotherapy. A boost of 5.4–9 
Gy (the lower dose if there is a concern about the 
volume of small bowel included in the boost ﬁ  eld) 
in 3–5 fractions at 1.8 Gy per fraction is adminis-
tered (see Fig. 2).
For the phase I treatment, the clinical target 
volume included the rectal tumour with a margin, 
the mesentery, and perirectal, presacral, internal 
iliac, external iliac and distal common iliac lymph 
nodes. The anterior margin was increased to 
include external iliac nodes if the primary tumour 
invaded bladder, prostate, cervix or vagina. The 
posterior margin included the sacrum. Lateral 
margins included the pelvic side-wall nodes. Supe-
rior margins are in the region the L5/S1 interspace, 
though for high rectal tumours, this margin may 
be increased to allow a 3 cm margin superior to 
the extent of the primary tumour, as identiﬁ  ed on 
pre-operative MRI. The inferior border depends 
upon the level of tumour within the rectum. For 
low rectal tumours within 3 cm of the anal verge 
the perineum is included, but where possible and 
allowing a 3cm margin below the inferior extent 
of the tumour, the muscles of the anal sphincter 
are spared.
The phase II volume covers assessable tumour 
(via MRI, CT, and clinical examination) with a 
2 cm margin.
Figure 1. Axial and Sagittal phase I planning CT showing planning target volume (thick line) and 95% isodose (thin line). Note a higher than 
standard superior border to cover primary disease with a 3 cm margin.
Figure 2. Axial and Sagittal phase II planning CT showing planning target volume (thick line) and 95% isodose (thin line). Note a 2 cm 
margin around the gross tumour volume (including nodal disease in the mesorectum), with anterior sacrum included.138
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Follow-up and assessment of toxicity
Patients were reviewed weekly during RT to 
assess toxicity. Those in a formal trial had detailed 
toxicity documentation as per trial protocol, while 
those treated outside of a trial setting had toxicity 
recorded according to departmental protocol. Four 
weeks after completion of CRT, acute toxicity 
was re-assessed with surgery following approxi-
mately two weeks later. Late toxicity was assessed 
at each subsequent follow-up visit. After surgery, 
patients were seen in clinic at three-monthly inter-
vals for the ﬁ  rst year, six-monthly for the next two 
years, and then yearly until ﬁ  ve years had elapsed 
post-operatively. Clinical examination, digital rec-
tal examination where appropriate, and tumour 
marker (Carcinoembryonic Antigen) were assessed 
at each visit. A CT thorax, abdomen, pelvis was 
routinely performed at one and two years post-
operatively. Clinical or radiological suspicion of 
local recurrence necessitated MRI pelvis for ana-
tomical deﬁ  nition, and pathological conﬁ  rmation.
Histopathology
All resections were performed with curative intent. 
Histopathologic assessment was performed accord-
ing to Royal College of Pathologists guidelines 
(Quirke P, 1998). In cases of apparent histopatho-
logical complete response, multiple blocks 
throughout the entire rectum were obtained.
Chemotherapy
Details of neo-adjuvant, concomitant and adjuvant 
chemotherapy are summarized in Table 1. Depart-
mental policy for concomitant chemotherapy is 
oral Capecitabine 825 mg/m
2 twice daily, including 
weekends.
Statistical analysis
Survival was analysed using the Kaplan-Meier 
method. 95% conﬁ  dence intervals were calculated 
using the binomial distribution.
Table 1. Neo-adjuvant, concomitant, and adjuvant chemotherapy.
Regime Number  Dose  Comment
Neo-Adjuvant    
Oxaliplatin-based 12  Oxaliplatin 130 mg/m
2 IV   7 × 4 cycles app; 1 
    once every 3 weeks;   required treatment 
   Capecitabine 1000 mg/m
2   cessation, 4 completed 4 
   BD  PO  × 14 days, 7 days rest  cycles with dose reductions
MMC-based 4  MMC 7 mg/m
2 IV bolus   3 Completed app; 1 × 
    every 6 weeks; -and either-   minor 5-FU dose-
   5-FU IVI 300 mg/m
2 /day ×   reduction.
   12  weeks  -or- Capecitabine  
   1250  mg/m
2 BD PO x 14 days  
   every  21  days 
5-FU alone  1  Weekly bolus 400 mg/m
2 × 5  Completed app
Concomitant    
Capecitabine 10  825  mg/m
2 BD PO  8 Completed app; 2 × 
      25% dose reductions
5-FU  3  IVI 200 mg/m2/day -OR- 300   2 Completed app; 1 dose
   mg/m
2 weekly bolus  reduction gr IV diarrhoea
Adjuvant    
Oxaliplatin/Capecitabine  2  (as neo-adjuvant)  2 Completed app
MMC-based  2  (as neo-adjuvant)  2 Completed app
Capecitabine 6  825  mg/m
2 BD PO for 14 days,  2 Completed app; 3 × 
    7 days rest  25%dose reductions;1
     discontinued  (metastases)
5-FU 2  IVI  200  mg/m
2 weekly for 6   1 dose reduction gr IV 
    weeks (i.e. 50% dose   diarrhoea; 1 Completed 
    reduction); IVI 400 mg/m
2/day app
    weekly for 12 weeks 
Abbreviations: IV: Intravenous; PO: per oral (by mouth); app: as per protocol; MMC: Mitomycin-C; IVI: Intravenous infusion; 
5-FU: 5-Fluorouracil.139
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Results
Patient characteristics
Of the 17 patients reviewed, 9 were male and 8 
female. Median age at diagnosis was 61 years 
(range 27–79). By the radiological criteria outlined 
above, 8 (47%) patients had tumours in the upper 
rectum, 5 (29.4%) in the recto-sigmoid, and 4 
(23.5%) in the distal sigmoid. Eight patients had 
been recruited into the ‘EXPERT’ trial, a phase II 
study of neo-adjuvant Oxaliplatin and Capecitabine 
and pre-operative CRT with concomitant 
Capecitabine, for patients with locally advanced 
and inoperable rectal cancer (Chau et al. 2006). 
Four further patients were treated off-study 
according to the ‘EXPERT’ protocol. Three 
patients were treated off-study according to the 
protocol of an earlier trial at the Royal Marsden 
of 12 weeks of neo-adjuvant protracted infusional 
5-Flourouracil and Mitomycin-C both prior to 
CRT and 12 weeks post-operatively (Chau et al. 
2003). One patient was recruited into a phase II 
trial of Capecitabine and Mitomycin-C as initial 
treatment for patients with metastatic colorectal 
cancer (Rao et al. 2004).
Treatment outcome
Median follow-up is 37 months (range 32–64 
months). Overall survival is 82.35% and disease 
free survival 70.59%. Loco-regional relapse rate 
is 5.88% (1 patient, pre-sacral recurrence). Two 
further patients, both of whom have died, had 
peritoneal disease, which was interpreted as meta-
static. All end-points were calculated from the ﬁ  rst 
day of neo-adjuvant therapy. We did not attempt a 
univariate analysis of tumour position due to small 
numbers.
Radiotherapy
All patients received long-course RT as described. 
Fifteen patients received 54 Gy in 30 fractions in 
2 phases, 2 patients 50.4 in 28 fractions. There were 
no gaps in treatment as a result of toxicity.
Chemotherapy
All patients received neo-adjuvant chemotherapy. 
Twelve patients were administered 4 cycles of 
neo-adjuvant Oxaliplatin/Capecitabine within the 
‘EXPERT’ protocol or with the same protocol 
‘off-trial’. Seven completed 4 cycles as per 
protocol. Of the remaining 5, only 1 patient 
required treatment cessation, the remainder com-
pleting 4 cycles with dose reductions. Four patients 
tolerated neo-adjuvant Mitomycin-C based regi-
mens well, with only 1 patient requiring a minor 
5-Flourouracil dose-reduction.
Thirteen patients tolerated concomitant chemo-
therapy well. Only 2 patients required a 25% dose 
reductions of Capecitabine. Eight patients com-
pleted adjuvant chemotherapy as per protocol. One 
patient discontinued adjuvant therapy due to 
development of pulmonary metastases. Two 
patients had dose reductions for grade III diar-
rhoea, 1 for grade IV diarrhoea, and 1 for grade 
III stomatitis.
Pathology
Clinical, and corresponding Pathological stages, 
are represented in Table 2. All patients had 
threatened surgical resection margins by MRI 
criteria. For T3 tumours, this margin could be 
threatened by tumour or nodal disease within 
1 mm or at the mesorectal fascia, or a surgical 
margin could be threatened by virtue of T4 dis-
ease. All patients underwent TME. Three patients 
had cT4 disease, while 1 could not be distin-
guished between T3b and T4. One patient with a 
cT4N2M0 tumour inﬁ  ltrating towards the left 
pelvic side wall and encasing external iliac ves-
sels had a positive pathological circumferential 
resection margin (ypT3N1M0). All others under-
went R0 resection. On initial pre-treatment MRI, 
2 patients had pelvic side wall nodes, 1 had an 
inferior mesenteric node, 2 had tumour directly 
invading the pelvic side wall, and 1 a nodule near 
the sacrum on meso-rectal fascia. Nine patients 
(52.9%) achieved a lower pathologic disease 
AJCC stage (2002) following neo-adjuvant 
therapy and surgery, i.e. were ‘downstaged’. This 
is demonstrated by Patient 1, sagittal (Fig. 3a and 
3b) and axial MR views (Fig. 4a and 4b), with 
corresponding histopathology (Fig. 4c). Six 
patients (35.3%) achieved a complete pathologi-
cal response despite 2 of these being cT4 and a 
third a borderline T4. Complete pathological 
response is demonstrated by Patient 2, sagittal 
(Fig. 5a and 5b) and axial MR views (Fig. 6a and 
6b) of the same patient, with corresponding his-
topathology (Fig. 6c).Three patients were 
converted from cT4 to ypT3. Two patients 140
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assigned cN2 on pre-treatment MRI proved 
ypN0.
Acute and late toxicity
Acute and late toxicities are shown in Table 3. Acute 
toxicity is demonstrated using the acute RTOG 
scoring system (acute cutaneous toxicity was not 
included). Only 1 patient suffered a grade III toxic-
ity, while there were no grade IV acute toxicities. No 
patient required a gap in treatment during CRT.
Late toxicity is presented with the Lent-Soma 
system. There were 3 grade III and 3 grade IV late 
toxicities.
Table 2. Clinical and corresponding Pathological stages.
Clinical TNM Clinical  Pathological TNM Pathological  Downstaged
stage stage
cT3bN1M0  IIIb ypT0N0M0 pCR Yes
cT3bNxM0 ? ypT3N2M0 IIIc No
cT3cN1M0 IIIb ypT0N0M0 pCR Yes
cT3cN1M0 IIIb ypT3N1M0 IIIb No
cT3cN2M0 IIIc ypT3N0M0 IIb Yes
cT3dN1M0 IIIb distal ypT3N0M0, IIb Yes
proximal ypT1N0M0
cT3dN2M0 IIIc ypT0N0M0 pCR Yes
cT4N0M0 IIb ypT3N1M0 IIIb No
cT4N0M0 IIb ypT4N0M0 IIb No
cT4N0M0 IIb ypT3N0M0 IIb No
cT4N1M0 IIIb ypT0N0M0 pCR Yes
cT4N1M0 IIIb ypT3N1M0 IIIb No
cT4N2M0 IIIc ypT3N1M0 CRM +ve IIIb No
cT4N2M0 IIIc ypT0N0M0 pCR Yes
cT4N2M0 IIIc ypT4N0M0 IIb Yes
cT3b/T4N1M0 IIIb ypT0N0M0 pCR Yes
cT3cN2M1 IV ypT3N1M1 IV No
Abbreviations: pCR: pathological complete response (no stage currently describes this).
Figure 3. Patient 1: Sagittal T2 weighted fast spin echo (TR3900 TE 120) MRI scans of a) pre-chemoradiotherapy, showing a large rectal 
tumour (open arrow) almost entirely above the peritoneal reﬂ  ection (arrow), and b) marked tumour regression and downsizing 4 weeks 
post-chemoradiotherapy, with areas of low signal intensity indicating ﬁ  brosis (open arrow).141
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Discussion
This series was comprised of patients with high-
risk locally advanced tumours situated either high 
in the rectum, the recto-sigmoid or distal sigmoid. 
All were at risk of involved surgical margins by 
pre-operative radiological criteria. In spite of this, 
more than a third (35.3%) of patients achieved a 
pathological complete response, and clear margins 
were attained in all but one patient. More than half 
of the patients (52.9%) had their tumours ‘down-
staged’ and CRT was delivered with minimal early 
and late side-effects, achieving a 3-year survival 
Figure 4. Patient 1: Coronal oblique imaging axial to Recto—Sigmoid, T2 weighted fast spin echo (TR4000 TE 120) MRI scans demonstrat-
ing: evidence of Recto-Sigmoid adenocarcinoma downstaging with neoadjuvant chemoradiotherapy. a) Annular tumour invading extensively 
into the mesorectum, with a threatened circumferential surgical margin (arrow) and tumour also appears to have perforated through the peri-
toneal reﬂ  ection (open arrow). Preoperative chemoradiotherapy was administered. b) Scans 4 weeks following completion of therapy. There 
has been remarkable tumour regression, with low signal intensity indicating ﬁ  brosis (arrow) and margins no longer appear threatened. There 
is ﬁ  brosis (low signal intensity) at the peritoneal reﬂ  ection. c) Surgical specimen conﬁ  rms ﬁ  brosis (arrows). This was an R0 resection.
Figure 5. Patient 2: Sagittal T2 weighted fast spin echo (TR3900 TE 120) MRI scans of a) pre-chemoradiotherapy, showing a large rectal 
tumour (open arrow) arising entirely above the peritoneal reﬂ  ection (arrowed) into the sigmoid colon, almost to the level of S1/2, and b) 
considerable tumour regression and downsizing 4 weeks post-chemoradiotherapy, with extensive low signal intensity indicating ﬁ  brosis 
(open arrow), consistent with a radiological complete response.142
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of 82.35% (95% CI 54.7–93.9), and a 3-year 
disease-free survival of 81.25% (95% CI 52.5–93.5). 
Long term results are awaited, though it is 
anticipated that such a degree of down-staging will 
be associated with a favorable long term outcome 
(Rodel et al. 2005; Mawdsley et al. 2005; Balch 
et al. 2003; Shivnani et al. 2004). Our data there-
fore suggests that such high-risk locally advanced 
high rectal and recto-sigmoid tumours may be 
treated with pre-operative CRT with acceptable 
toxicity and impressive down-staging, rendering 
clear surgical margins in most patients, with an 
excellent short term outcome.
All patients underwent optimal surgery with 
TME, as described by Heald (Heald and Ryall, 
1986). CRM status has emerged as one of the most 
important prognostic determinants following TME 
(Mawdsley et al. 2005). The ability of pre-operative 
MRI to accurately predict CRM status has been 
validated recently in a multi-centre European trial 
(MERCURY, 2006).
All of the patients in this series received neo-
adjuvant chemotherapy prior to concomitant CRT. 
It is now established that this approach for locally 
advanced rectal cancer results in excellent down-
staging, pCR rates and margin negativity (Chau 
Figure 6. Patient 2: Oblique axial T2 weighted fast spin echo (TR4000 TE 120) MRI scans demonstrating evidence of Recto-Sigmoid 
adenocarcinoma downstaging with neoadjuvant chemoradiotherapy. a) Near circumferential tumour abuts (arrowed) the peritoneal surface 
and ﬁ  broid uterus. Preoperative chemoradiotherapy was delivered. b) Scans 4 weeks following completion of therapy. There has been very 
considerable tumour regression, with extensive low signal intensity indicating ﬁ  brosis (arrowed). Appearances are in keeping with a radio-
logical complete response. c) Surgical specimen conﬁ  rms ﬁ  brosis (arrowed) and was a pathological complete response.
Table 3. Acute (RTOG) and Chronic (LENT-SOMA) toxicities.
Toxicity Grade I Grade II Grade III Grade IV
EARLY
Bowel 56 1 0
Bladder 63 0 0
LATE
Small Bowel
frequency 6 5 0 1
consistency 4 5 2 0
pain 1 2 0 0
Bladder
frequency 1 0 1 0
Decreased stream 0 1 0 0
Rectum
frequency 4 4 0 1
pain 0 2 0 0
sphincter 4 2 2 0
mucus 2 1 0 0
tenesmus 0 0 0 1
The highest late toxicity experienced is displayed, e.g. 4 patients experienced grade I urinary frequency, and no higher.143
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et al. 2006). In the EXPERT study patients with 
MRI—deﬁ  ned poor risk features were treated with 
4 cycles of neoadjuvant Oxaliplatin and 
Capecitabine prior to radiotherapy with concomi-
tant Capecitabine. The schedule was well tolerated, 
and 87% of patients proceeded to surgery 6 weeks 
after completing radiotherapy. The pathological 
complete response rate was 24% and specimens 
with only microscopic residual tumour foci 
accounted for a further 48%. Because of the effec-
tiveness of this schedule in tumours with a threat-
ened circumferential margin within the rectum, the 
same schedule was applied to those patients with 
higher tumours. An additional imperative for the 
addition of neoadjuvant chemotherapy may be the 
early treatment of micro-metastatic disease with 
the aim of reducing the rate of subsequent systemic 
relapse. Conﬁ  ning chemotherapy to that given 
concomitantly with radiotherapy has not had an 
impact in overall survival in a randomised trial of 
preoperative RT versus CRT in T3-4 Rectal Can-
cers, despite the addition of this concomitant 
chemotherapy producing superior downstaging 
(Gerard JP et al. 2005). This implies that con-
comitant chemotherapy provides effective radio-
sensitisation but is not tumoricidal, whether by 
choice of agent or dose, in terms of eradicating 
micro-metastases. It will be fundamental to the 
testing of the EXPERT schedule that a reduction 
in metastatic disease and superior disease free 
and overall survival will result from inclusion of 
neoadjuvant chemotherapy. Furthermore, 
although there may be a sound basis for giving 
this extent of chemotherapy neo-adjuvantly, it 
must permit tolerable delivery of the other 
contributing treatment modalities, surgery and 
radiotherapy.
No ﬁ  xed bony landmark exists to distinguish 
the recto-sigmoid junction, nor is the distance 
from the anal margin a reliable or reproducible 
surrogate. The key pre-operative RT trials did not 
have the benefit of MRI, and therefore used 
sigmoidoscopic distance from the anal verge. The 
deﬁ  nition for upper border of ‘rectum’ has not 
been consistent between trials, and thus varying 
degrees of distal sigmoid and recto-sigmoid 
tumours have been included. The German Rectal 
Cancer Study Group accepted all tumours with 
an inferior border within 16 cm of anal verge 
(Sauer et al. 2004); tumours in the Swedish Rectal 
Cancer Trial had to be below the sacral promon-
tory on a lateral barium enema (1997). The Dutch 
Colorectal Cancer Group used an amalgamation 
of these policies, an inferior border not further 
than 15 cm from the anal verge and below the 
level of S1-2 (Kapiteijn et al. 2001). This strongly 
implies that signiﬁ  cant numbers of distal sigmoid 
and recto-sigmoid tumours were included in these 
trials.
In the Dutch trial, location was a signiﬁ  cant 
predictor of local recurrence. RT had no effect on 
local recurrence for tumours between 10 and 15 cm 
from the anal verge, with a hazard ratio of 1.00 
(p = 0.17). This result supports the prejudice 
against neo-adjuvant RT for treating higher rectal 
cancers.
The Swedish group did not perform a univariate 
analysis to review the relative local control beneﬁ  t 
depending on the location of tumour within the 
rectum (1997). Nor have the two major met-
analyses of pre-operative and post-operative RT 
investigated this (Camma et al. 2000, 2001). Only 
one of the adjuvant RT trials after 1990, used in 
these meta-analyses, has performed a univariate 
analysis of different anatomical parts of the rectum 
and there was no demonstrable impact on outcome 
(Treurniet-Donker et al. 1991).
These trials therefore appear to have routinely 
included distal sigmoid and recto-sigmoid tumours, 
which may not beneﬁ  t from ‘routine’ pre-operative 
radiotherapy. The rationale for irradiating tumours 
above the peritoneal reﬂ  ection is far less well 
established than is the case for rectal tumours. 
These high tumours generally fail in a colonic pat-
tern with peritoneal, rather than local failure, 
though high local recurrence rates have been 
reported, and this would support the application of 
a neo-adjuvant strategy, similar to the approach to 
rectal cancer (Pilipshen et al. 1984).
To our knowledge, no series of neo-adjuvant 
CRT exists for sigmoid or colonic tumours. Willett 
et al. at the Massachusetts General Hospital pub-
lished the largest retrospective series of adjuvant 
RT for colonic tumours (n = 203) (Willett et al. 
1984). This included patients with colonic T4N0M0 
tumours, T3N1-2 in anatomically ‘immobile’ 
regions (i.e. retroperitoneal), and selected high risk 
T3N0 tumours with close margins. Patients were 
treated with adjuvant RT (45 Gy with a 5 cm mar-
gin), without concomitant chemotherapy. Treated 
patients were compared to a historical group 
(n = 395) treated with surgery only. There was a 
local control and disease-free survival (DFS) 
advantage for T4N0M0 (DFS 80%), and T4N+M0 144
O’Neill et al
Clinical Medicine: Oncology 2008:2 
(DFS 53%) tumours, and for T3N0 tumours with 
a perforation or ﬁ  stula. There was a 37% 5-yr DFS 
in those having RT following R2 resection 
(i.e. gross disease left in-situ). Ten year results 
conﬁ  rm these outcomes, especially in the T4N0 
subset (Willett et al. 1993).
Intergroup-0130 was developed based on the 
Willett’s data but, unfortunately, this trial accrued 
poorly and was closed prematurely (Martenson et al. 
2004). The trial design was a randomisation to test 
the effect of adding radiotherapy to adjuvant che-
motherapy. The available data indicates that toxicity 
was acceptable although there was no overall sur-
vival or disease free survival advantage.
While there is a reasonable rationale to treat 
certain high—risk colonic tumours with adjuvant 
therapy, the evidence-base supporting either RT or 
CRT for sigmoid and colonic tumours is less robust 
than for rectal cancers, and there is no body of 
neo-adjuvant evidence. It is also apparent that 
randomised trials to date have included distal sig-
moid and recto-sigmoid tumours, which may not 
beneﬁ  t from ‘routine’ pre-operative RT or CRT.
Conclusion
High rectal, recto-sigmoid and distal sigmoid 
tumours have not been accurately identiﬁ  ed and 
reported in a trial to date. This series suggests that 
those that are T4 or have a threatened circumferential 
resection margin may be treated with pre-operative 
Chemo-Radiotherapy with acceptable toxicity and 
excellent downstaging, facilitating R0 resection 
and favorable short term outcome.
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